Press Releases for GTXI

Press Releases
GTx Inc. (GTXI) Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell
GTx, Inc. Reports Second Quarter 2009 Corporate Results
GTx, Inc. Announces Second Quarter 2009 Corporate Results Conference Call and Webcast
GTx-758, an Oral LH Inhibitor for First Line Treatment of Advanced Prostate Cancer, Advances into Second Phase I Clinical Trial
GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting
GTx Announces Ostarine™ (MK-2866) Clinical Trial Data to be Presented at ENDO 2009
GTx Announces Webcast of Corporate Presentation at Goldman Sachs 30th Annual Global Healthcare Conference
GTx's Toremifene 80 Mg Increased Bone Mineral Density in Multiple Clinically Relevant Subpopulations of Prostate Cancer Patients on Androgen Deprivation Therapy
GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data to be Presented at the Annual Meeting of the American Society of Clinical Oncology
GTx, Inc. Reports First Quarter 2009 Results
GTx, Inc. Announces First Quarter 2009 Corporate Results Conference Call and Webcast
First Ever Prospective Fracture Study in Prostate Cancer Patients on ADT Reveals These Men Are at High Risk for Skeletal Fractures
GTx, Inc. Appoints Michael K. Brawer, MD as Executive Director, Medical Affairs and Clinical Development
GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data to be Presented at the Annual Meeting of the American Urological Association
GTx Announces Upcoming Investor Conference Presentations
GTx Announces Corporate Presentation at the Cowen and Company 29th Annual Health Care Conference
FDA Provides PDUFA Target Agency Action Date For GTx’s Toremifene 80 mg NDA
GTx Announces Phase III Clinical Development of Toremifene 20 mg on Course Following Planned Safety Review - Feb 26 2009 7:21AM
GTx Announces Toremifene 80 mg NDA Accepted for Review by FDA
GTx Reports Fourth Quarter and Year End 2008 Results - Feb 17 2009 8:44AM
GTX Reports Fourth Quarter and Year End 2008 Results - Feb 17 2009 6:15AM
GTx, Inc. Announces Fourth Quarter and Year End 2008 Corporate Results Conference Call and Webcast
GTx Announces Webcast of Corporate Presentation at the 11th Annual BIO CEO & Investor Conference
GTx Congratulates Dr. Duane D. Miller on His Induction into the American Chemical Society Medicinal Chemistry Hall of Fame
GTx Announces Conference Call to Discuss EMEA Label Changes to Fareston®
GTx Announces Webcast of Corporate Presentation at the 27th Annual JP Morgan Healthcare Conference
GTx Submits New Drug Application for Toremifene 80 mg for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy
GTx Announces Corporate Presentation at Lazard Capital Markets Annual Healthcare Conference
GTx, Inc. Reports Third Quarter 2008 Financial Results
GTx Announces Corporate Presentation at Rodman & Renshaw Annual Healthcare Conference
GTx, Inc. Announces Third Quarter 2008 Financial Results Conference Call and Webcast
GTx Announces Presentation of Toremifene 80 mg Data at Fourth Annual Chicago Supportive Oncology Conference
GTx Announces Investigational Ostarine(TM) (MK-2866) Met the Primary Endpoint in the Phase II Cancer Cachexia Clinical Trial
GTx to Present at the UBS Global Life Sciences Conference
GTx Presents Bone Turnover Marker Data and Additional PSA Progression Safety Analysis for Toremifene 80 mg Phase III ADT Clinical Trial
GTx to Present Additional Efficacy and Safety Analyses from the Toremifene 80 mg Phase III ADT Clinical Trial at the Annual Meeting of the American Society for Bone and Mineral Research
GTx Announces Webcast of Corporate Presentation at the NewsMakers in the Biotech Industry Conference
GTx, Inc. Reports Second Quarter 2008 Financial Results
GTx Announces Phase III Clinical Development of Toremifene 20 mg on Course Following Planned Safety Review - Jul 28 2008 6:11AM
GTx, Inc. Announces Second Quarter 2008 Financial Results Conference Call and Webcast
GTx Announces Webcast of Corporate Presentation at Goldman Sachs 29th Annual Global Healthcare Conference
GTx Announces Phase III PIN Clinical Trial Will Continue As Planned - May 26 2008 10:32PM
GTx, Inc. Reports First Quarter 2008 Financial Results - Jun 3 2008 3:15AM
GTx Appoints Kenneth S. Robinson, MD to the Board of Directors - Jun 3 2008 3:13AM
GTx, Inc. Announces First Quarter 2008 Financial Results Conference Call and Webcast
First Fracture Prevention Study in Men Receiving ADT for Prostate Cancer Presented at AACR Annual Meeting
GTx Announces Upcoming Presentation of Toremifene Citrate 80 mg Phase III ADT Clinical Trial Results
GTx Announces Webcast of Corporate Presentation at the Bank of America 2006 Specialty Pharmaceuticals Conference
GTx Announces Webcast of Corporate Presentation at R.W. Baird & Co. 2006 Focus on Oncology Conference
GTx, Inc. Reports Second Quarter 2006 Financial Results
GTx, Inc. Completes Enrollment of Phase II Ostarine Trial